The December 10, 2019, article by Plotkin et al entitled “Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma” (J Clin Oncol 10.1200/JCO.19.01367) was published with an error.
The Acknowledgments section read as:
ACKNOWLEDGMENT
We thank Karen Cole-Plourde and Vivien Philips for their assistance. We thank Dana-Farber/Harvard Cancer Center in Boston, Massachusetts, for the use of the Tumor Imaging Metrics Core, which provided centralized imaging service.
It should have read as:
ACKNOWLEDGMENT
Research support for this study was provided by Genentech. We thank Rakesh Jain, PhD, for his guidance and support of the biomarker analysis in this trial and Karen Cole-Plourde and Vivien Philips for their help with trial coordination. We thank Dana-Farber/Harvard Cancer Center in Boston, MA, for the use of the Tumor Imaging Metrics Core, which provided centralized imaging service. Dana-Farber/Harvard Cancer Center is supported in part by NCI Cancer Center Support Grant No. NIH 5 P30 CA06516.
This has been corrected as of January 15, 2020. The authors apologize for the error.